Next-Generation Retinal Disease Treatments: Advancing Care in nAMD and DME
Michael A. Klufas, MD, discusses how second-generation retinal vascular agents like high-dose aflibercept 8 mg and faricimab show promising results for treating neovascular AMD and diabetic macular edema, with particular emphasis on extended treatment intervals up to 20 to 24 weeks and strategies for managing persistent exudation while maintaining vision.
EP. 2: Case 2: Treatment-Naive DME with Gradual Visual and Anatomical Gains Using Aflibercept 8 mg
May 1st 2025A panelist discusses how a man aged 79 years with long-duration diabetes and treatment-naive diabetic macular edema (DME) responded well to aflibercept 8-mg therapy, progressing from 4-week loading doses to an extended 10-week interval with resolution of macular edema and improved vision from 20/60 to 20/30.
EP. 3: Case 3: Achieving Rapid Fluid Resolution in nAMD With Faricimab
May 1st 2025A panelist discusses how a woman aged 77 years with bilateral neovascular age-related macular degeneration (nAMD) demonstrated different responses to treatments between her eyes, showing a superior response to faricimab in her right eye compared with ranibizumab, highlighting how some patients may respond better to specific anti-VEGF agents.
